Capital Advisory Group Advisory Services’s PhaseBio Pharmaceuticals, Inc. Common Stock PHAS Stock Holding History

Capital Advisory Group Advisory Services’s Portfolio PHAS Stock Details PHAS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q2	–	Sell	-2,800	Closed	-$4K	–	514
2022 Q1	$4K	Buy	+2,800	New	+$4.54K	﹤0.01%	455
2021 Q4	–	Sell	-2,800	Closed	-$9K	–	549
2021 Q3	$9K	Hold	2,800	–	–	﹤0.01%	411
2021 Q2	$10K	Hold	2,800	–	–	﹤0.01%	400
2021 Q1	$10K	Hold	2,800	–	–	﹤0.01%	388
2020 Q4	$9K	Hold	2,800	–	–	﹤0.01%	384
2020 Q3	$10K	Hold	2,800	–	–	0.01%	321
2020 Q2	$13K	Hold	2,800	–	–	0.01%	285
2020 Q1	$9K	Buy	+2,800	New	+$12.8K	0.01%	248
2019 Q4	–	Sell	-2,800	Closed	-$12K	–	445
2019 Q3	$12K	Hold	2,800	–	–	0.01%	266
2019 Q2	$37K	Buy	+2,800	New	+$34.3K	0.02%	173

Other funds holding PHAS

NMC

NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return

APM

Avidity Partners Management Dallas, Texas $936M AUM 195% 1-Year Est. Return

RSCM

Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

MCM

MAI Capital Management Independence, Ohio $17.7B AUM 18.87% 1-Year Est. Return

Johnson & Johnson New Brunswick, New Jersey $652M AUM 198.07% 1-Year Est. Return

CHI Advisors New York $252M AUM 56.99% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Stifel Financial St. Louis, Missouri $109B AUM 21.36% 1-Year Est. Return

DCM

DAFNA Capital Management Los Angeles, California $440M AUM 109.12% 1-Year Est. Return

Capital Advisory Group Advisory Services's PHAS Position: Q2 2022 in Review

Capital Advisory Group Advisory Services sold out of PhaseBio Pharmaceuticals, Inc. Common Stock (PHAS) in Q2 2022, closing a stake of 2,800 shares — an estimated $4K sold.

Capital Advisory Group Advisory Services first reported a position in PHAS in Q2 2019 and held it in 10 quarters. The position peaked at $37K in Q2 2019. 49 funds tracked by Wall St. Rank hold PHAS as of Q2 2022.

Capital Advisory Group Advisory Services reported no remaining PhaseBio Pharmaceuticals, Inc. Common Stock position as of Q2 2022 after selling out during the quarter.
Capital Advisory Group Advisory Services sold 2,800 PhaseBio Pharmaceuticals, Inc. Common Stock shares in Q2 2022, an estimated $4K.
Capital Advisory Group Advisory Services first reported a position in PhaseBio Pharmaceuticals, Inc. Common Stock in Q2 2019 and held it in 10 quarters.
Capital Advisory Group Advisory Services's PhaseBio Pharmaceuticals, Inc. Common Stock position peaked at $37K in Q2 2019.
49 funds tracked by Wall St. Rank held PhaseBio Pharmaceuticals, Inc. Common Stock as of Q2 2022.

Based on Capital Advisory Group Advisory Services's 13F filing for Q2 2022, filed 12 Aug 2022.